Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
NCT ID: NCT01824225
Last Updated: 2015-10-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2013-03-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
NCT03468296
Intense Treatment Regimen With Intravitreal Aflibercept Injection
NCT03594461
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
NCT02305238
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
NCT02718326
Maximum Treatment Interval With Aflibercept T&E
NCT05342857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PRN injection of aflibercept
Intravitreal aflibercept
Aflibercept
Two months injection of aflibercept
Intravitreal afilibercept
Aflibercept
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aflibercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Visual acuity above 0.1 in decimal visual acuity
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nihon University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Koji Tanaka
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mitsuko Yuzawa, M.D.
Role: STUDY_CHAIR
Surugadai Nihon University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Surugadai Nihon university hospital
Chiyoda-ku, Tokyo, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NihonU-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.